ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
IND for phase 2b/3 trial submitted to the FDA Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering novel approac...
As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement ha...
© 2025 Biopharma Boardroom. All Rights Reserved.
